🚀 VC round data is live in beta, check it out!
Edgewise Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Edgewise Therapeutics and similar public comparables like Virbac, Voronoi, TransThera Sciences, Zhejiang Huahai and more.
Edgewise Therapeutics Overview
About Edgewise Therapeutics
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company’s product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
Founded
2017
HQ
Employees
110
Website
Sectors
Financials (LTM)
EV
$3B
Edgewise Therapeutics Financials
Edgewise Therapeutics reported last 12-month revenue of — and negative EBITDA of ($200M).
In the same LTM period, Edgewise Therapeutics generated — in gross profit, ($200M) in EBITDA losses, and had net loss of ($184M).
Revenue (LTM)
Edgewise Therapeutics P&L
In the most recent fiscal year, Edgewise Therapeutics reported revenue of — and EBITDA of ($189M).
Edgewise Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($200M) | XXX | ($189M) | XXX | XXX | XXX |
| Net Profit | ($184M) | XXX | ($168M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Edgewise Therapeutics Stock Performance
Edgewise Therapeutics has current market cap of $4B, and enterprise value of $3B.
Market Cap Evolution
Edgewise Therapeutics' stock price is $32.82.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $4B | -2.1% | XXX | XXX | XXX | $-1.56 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialEdgewise Therapeutics Valuation Multiples
Edgewise Therapeutics trades at (15.0x) EV/EBITDA.
Edgewise Therapeutics Financial Valuation Multiples
As of April 11, 2026, Edgewise Therapeutics has market cap of $4B and EV of $3B.
Equity research analysts estimate Edgewise Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Edgewise Therapeutics has a P/E ratio of (19.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/EBITDA | (15.0x) | XXX | (15.8x) | XXX | XXX | XXX |
| EV/EBIT | (14.5x) | XXX | (15.7x) | XXX | XXX | XXX |
| P/E | (19.1x) | XXX | (21.0x) | XXX | XXX | XXX |
| EV/FCF | (20.7x) | XXX | (20.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Edgewise Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Edgewise Therapeutics Margins & Growth Rates
Edgewise Therapeutics' revenue in the last fiscal year grew by —.
Edgewise Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.7M for the same period.
Edgewise Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 17% | XXX | 19% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.7M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Edgewise Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Virbac | XXX | XXX | XXX | XXX | XXX | XXX |
| Voronoi | XXX | XXX | XXX | XXX | XXX | XXX |
| TransThera Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Zhejiang Huahai | XXX | XXX | XXX | XXX | XXX | XXX |
| J.B. Chemicals & Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Edgewise Therapeutics M&A Activity
Edgewise Therapeutics acquired XXX companies to date.
Last acquisition by Edgewise Therapeutics was on XXXXXXXX, XXXXX. Edgewise Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Edgewise Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialEdgewise Therapeutics Investment Activity
Edgewise Therapeutics invested in XXX companies to date.
Edgewise Therapeutics made its latest investment on XXXXXXXX, XXXXX. Edgewise Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Edgewise Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Edgewise Therapeutics
| When was Edgewise Therapeutics founded? | Edgewise Therapeutics was founded in 2017. |
| Where is Edgewise Therapeutics headquartered? | Edgewise Therapeutics is headquartered in United States. |
| How many employees does Edgewise Therapeutics have? | As of today, Edgewise Therapeutics has over 110 employees. |
| Who is the CEO of Edgewise Therapeutics? | Edgewise Therapeutics' CEO is Kevin Koch. |
| Is Edgewise Therapeutics publicly listed? | Yes, Edgewise Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Edgewise Therapeutics? | Edgewise Therapeutics trades under EWTX ticker. |
| When did Edgewise Therapeutics go public? | Edgewise Therapeutics went public in 2021. |
| Who are competitors of Edgewise Therapeutics? | Edgewise Therapeutics main competitors are Virbac, Voronoi, TransThera Sciences, Zhejiang Huahai. |
| What is the current market cap of Edgewise Therapeutics? | Edgewise Therapeutics' current market cap is $4B. |
| Is Edgewise Therapeutics profitable? | No, Edgewise Therapeutics is not profitable. |
| What is the current EBITDA of Edgewise Therapeutics? | Edgewise Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Edgewise Therapeutics? | Current EBITDA multiple of Edgewise Therapeutics is (15.0x). |
| What is the current FCF of Edgewise Therapeutics? | Edgewise Therapeutics' last 12 months FCF is ($145M). |
| What is the current EV/FCF multiple of Edgewise Therapeutics? | Current FCF multiple of Edgewise Therapeutics is (20.7x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.